Section Edited by Howard L. Kaufman, MD, FACS
This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.
Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune responseHaoran Zhu, Wanrong Zhang, Qingguo Guo, Ruoyue Fan, Guangzuo Luo, Ying Liu
29 November 2024
Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapyMarisa Lenga, Esther Choi, Jeffrey Sosman, Sunandana Chandra, Danielle Lam, Kirsten Johnson, Lauren Schiemann, Jennifer Choi
19 November 2024
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumorsDiwakar Davar, Benedito A Carneiro, Grace K Dy, Siddharth Sheth, Mitesh J Borad, Kevin J Harrington, Sandip P Patel, Evanthia Galanis, Adel Samson, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Eric TuSee the full list of authors
17 November 2024
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analysesThomas Pulliam, Saumya Jani, Peter H Goff, Rashmi Bhakuni, Shira Tabachnick-Cherny, Kimberly Smythe, Brandon W Seaton, Lisa Tachiki, Rima Kulikauskas, Candice Church, David M Koelle, Paul Nghiem, Shailender Bhatia
14 October 2024
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumorsFei Zhu, Zheng Lu, Wenjing Tang, Guangya Zhao, Yingxiang Shao, Bowen Lu, Jiage Ding, Yanyan Zheng, Lin Fang, Huizhong Li, Gang Wang, Renjin Chen, Junnian Zheng, Dafei Chai
28 August 2024
Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunityTaylor J Moon, Hieu Minh Ta, Anubhuti Bhalotia, Kai E Paulsen, Diarmuid W Hutchinson, Gabrielle M Arkema, Andrew S Choi, Michiko G Haynie, Laolu Ogunnaike, Margee Dever, Li Lily Wang, Efstathios Karathanasis
28 August 2024
Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cellsKristin DePeaux, William G Gunn, Dayana B Rivadeneira, Greg M Delgoffe
17 August 2024
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signallingEdward Armstrong, Matthew K L Chiu, Shane Foo, Lizzie Appleton, Pablo Nenclares, Anton Patrikeev, Nitya Mohan, Martin Mclaughlin, Galabina Bozhanova, Julia Hoebart, Victoria Roulstone, Emmanuel Patin, Malin Pedersen, Joan Kyula, Masahiro OnoSee the full list of authors
25 July 2024
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironmentFadi Azar, Jules Deforges, Christelle Demeusoit, Patricia Kleinpeter, Christelle Remy, Nathalie Silvestre, Johann Foloppe, Laetitia Fend, Clémentine Spring-Giusti, Eric Quéméneur, Jean-Baptiste Marchand
25 July 2024
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cellsRichard Baugh, Hena Khalique, Emma Page, Janet Lei-Rossmann, Peter Kok-Ting Wan, Timothy Johanssen, Daniel Ebner, Olaf Ansorge, Leonard W Seymour
9 May 2024